GRASTIM 300 MG PFS

About

Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that regulates the production and release of neutrophils from the bone marrow. It acts by binding to specific G-CSF receptors on hematopoietic stem cells and myeloid progenitor cells, stimulating their proliferation, differentiation, and functional activation. Clinically, filgrastim is used to reduce the incidence and duration of neutropenia, a condition characterized by abnormally low levels of neutrophils, which are crucial for fighting bacterial infections. This is particularly important in patients undergoing myelosuppressive chemotherapy, bone marrow transplantation, or those with severe chronic neutropenia. By increasing neutrophil counts, filgrastim helps to mitigate the risk of life-threatening infections and allows for the continuation of cancer treatments.

Uses

• Chemotherapy-induced neutropenia
• Bone marrow transplantation
• Severe chronic neutropenia
• Mobilization of peripheral blood progenitor cells

Directions For Use

Administer subcutaneously or intravenously as directed by your healthcare provider. Do not shake the pre-filled syringe.

Benefits

• Reduces incidence of febrile neutropenia.
• Shortens duration of neutropenia.
• Decreases risk of infection.
• Allows for timely chemotherapy cycles.
• Improves quality of life for neutropenic patients.
• Supports hematopoietic stem cell transplantation.

Side Effects

• Bone pain
• Myalgia (muscle pain)
• Fatigue
• Nausea
• Vomiting
• Diarrhea
• Headache
• Splenomegaly (enlarged spleen)
• Injection site reactions
• Alopecia (hair loss)
• Thrombocytopenia
• Leukocytosis

Safety Measures

• Alcohol - No specific contraindication, but excessive alcohol may exacerbate general fatigue or discomfort.
• Pregnancy - Use only if clearly needed; potential risks to the fetus should be weighed against maternal benefit.
• Breastfeeding - Caution advised; it is unknown if filgrastim is excreted in human milk.
• Liver - Generally considered safe; no specific dose adjustments are typically required for liver impairment.
• Kidney - Generally considered safe; no specific dose adjustments are typically required for kidney impairment.
• Lung - Monitor for acute respiratory distress syndrome (ARDS) or alveolar hemorrhage, especially in patients with underlying lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.